The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Announces Strengthening Sales

24 Oct 2011 07:00

RNS Number : 6687Q
Angle PLC
24 October 2011
 



For immediate release

24 October 2011

 

ANGLE plc

 

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES STRENGTHENING SALES

 

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, which specialises in computer games middleware, has made significant progress on a number of fronts.

 

Sales continue to grow at an encouraging rate. Geomerics' Enlighten technology is now being employed in 18 titles worldwide and is currently in evaluation and under consideration for many more. Among these titles are two of the most hotly anticipated games of 2011. Battlefield 3, from EA DICE, is released on 28th October. It is considered a challenger to Call of Duty's market dominance. The game has been backed by a $100m marketing campaign and has received high praise and multiple awards for the quality of its graphics, of which the lighting is driven by Geomerics' Enlighten engine. Battlefield 3 is followed by the release of Need for Speed: The Run on 18th November. This is the next game in one of the most successful franchises of all time and is built on the same Enlighten technology as Battlefield 3.

 

Geomerics is also delighted that it has secured its first deal inside Korea, which will see Enlighten used in multiple titles. This opens up a whole new market for Enlighten and, on the back of sales in Japan, demonstrates that Geomerics is on its way to establishing a strong base in the Asian market.

 

Geomerics' participation in Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme continues to go well and is yielding a range of new sales opportunities.

 

Finally, Geomerics has been awarded new grant funding to research applications of its technology on mobile devices. Geomerics will receive €470,000 over the next three years as part of a €2.8 million EU-funded project researching the next generation of graphics technology for mobile platforms.

 

 

 

Chris Doran, Founder of Geomerics, commented:

"At Geomerics we have tracked the rise in performance of mobile platforms very closely. It is clear that they are fast approaching console performance, and at the high end will overtake this in 2012. We are very excited about the prospect of taking our console technology to mobile platforms, and to contributing to joint R&D on the future direction of graphics technology for mobile devices."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are very pleased with the Geomerics' continued strong progress and look forward to the positive market impact when Battlefield 3 launches at the end of this week."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

About Geomerics www.geomerics.com

 

Geomerics is an innovation-led company developing cutting-edge graphics technology for the games industry. Based in Cambridge, UK, Geomerics has built a team that combines world-class management and games industry experience with some of the UK's leading researchers. Geomerics launched its groundbreaking Enlighten technology in 2009. Enlighten redefines how designers use and control lighting within a game.

 

Geomerics partners with many of the leading companies in the games industry and is currently working with developers around the world on AAA titles for release in 2011 and 2012. The first titles incorporating Enlighten include the highly anticipated 'Battlefield 3' and 'Need for Speed: The Run'.

 

For more details about Geomerics research into mobile platforms, visit www.lpgpu.org 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDGLBDBGBX
Date   Source Headline
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting
2nd Jul 20187:00 amRNSNotice of Preliminary Results
25th Jun 20186:20 pmRNSResults of Fundraising
25th Jun 20182:58 pmRNSClose of Accelerated Bookbuild
25th Jun 20187:50 amRNSProposed Placing of New Ordinary Shares
4th Jun 20187:00 amRNSENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14th May 20187:00 amRNSLeading cancer surgeon appointed
3rd May 20187:00 amRNSAngle & QIAGEN Poster
19th Apr 20187:00 amRNSParsortix in multiple presentations at AACR
19th Apr 20187:00 amRNSBreakthrough Research with Parsortix
5th Apr 20187:00 amRNSFirst patient enrolled in FDA study
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.